Orgenesis Inc. (NASDAQ:ORGS – Get Free Report) shares traded down 9.1% during mid-day trading on Monday . The company traded as low as $0.45 and last traded at $0.45. 100 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 1,185 shares. The stock had previously closed at $0.4950.
Orgenesis Stock Performance
The firm has a market capitalization of $2.33 million, a price-to-earnings ratio of -0.04 and a beta of 2.89. The business has a 50 day simple moving average of $0.39 and a 200-day simple moving average of $0.38.
Orgenesis Company Profile
Orgenesis, Inc is a cell and gene therapy company that develops and commercializes point-of-care manufacturing platforms for autologous and allogeneic therapies. The company offers an end-to-end solution that spans from R&D through clinical and commercial production, targeting applications in oncology, neurology, and various rare diseases. Orgenesis’ technology platforms are designed to streamline the complex processes involved in cell isolation, genetic modification, expansion and cryopreservation.
The company’s flagship offering is its automated Prodigy® platform, which integrates cell processing workflows into a closed, single-use system.
Further Reading
- Five stocks we like better than Orgenesis
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
